Accessibility Menu
Theravance Biopharma logo

Theravance Biopharma(NASDAQ) TBPH

Market Cap$878.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-26%
5 Year+29%
1 Year+29%
1 Month-0%
$16.95
+0.15%
+0.03Today
Theravance Biopharma last closing stock price
MetricPriceDate
Last closeUSD 16.922026-08-17
Theravance Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.06%USD 16.912026-08-10
1 month-0.06%USD 16.932026-07-17
3 month+4.12%USD 16.252026-05-19
Year to date-9.57%USD 18.712025-12-31
1 year+28.67%USD 13.152025-08-15
3 year+74.43%USD 9.702023-08-18
5 year+28.96%USD 13.122021-08-18
Since inception-26.31%USD 22.962014-05-16

Theravance Biopharma Financials at a Glance

Market Cap

$878.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$104.31M

Net Income (TTM)

$53.81M

EPS (TTM)

$1.01

P/E Ratio

16.76

Dividend

$0.00

Beta (Volatility)

0.61 (Low)

Price

$16.95

Volume

47,947.845

Open

$16.96

Previous Close

$16.92

Daily Range

$16.93 - $16.96

52-Week Range

$13.08 - $21.03

Estimated Earnings Date

Nov 10, 2026

TBPH News

GettyImages-516077862-1201x820-96628fa

Here's Why Shares in Theravance Biopharma Exploded Today

Lee SamahaNov 11, 2025
Foolcom-Featured.png

Theravance Sales Jump 83 Percent

Motley Fool Markets TeamAug 12, 2025
Stethescope atop US currency and insurance claim form

Why Theravance Biopharma Stock Dived 16% Today

Eric VolkmanSep 15, 2021
physician-icu-clipboard-getty

Here's Why Theravance Biopharma Stock Is Tanking Today

Cory RenauerAug 24, 2021
Man with hands on back of his head and stock chart

Why Theravance Biopharma Shares Are Sinking Today

Keith SpeightsFeb 12, 2020
GettyImages-843765220

Will Theravance Biopharma Finally Break Out in 2020?

David HaenJan 14, 2020
market crash image getty 2

Why Theravance Biopharma Inc Shares Tumbled 19.5% Today

Todd CampbellOct 27, 2016
take-long-view_large

Theravance Biopharma Inc Skyrocketed in October -- Here's Why

Brian FeroldiNov 8, 2015
Page 1

TBPH: Motley Fool Moneyball Superscore

47

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theravance Biopharma

Theravance Biopharma creates medicines for people with lung diseases. These products help patients breathe more easily every day. The company also builds treatments for rare blood pressure disorders.

The Product Portfolio

  • YUPELRI: Maintenance treatment for patients with chronic obstructive pulmonary disease; delivered as a once-daily mist through a nebulizer machine.
  • TRELEGY: Triple-therapy inhaler for asthma and COPD; provides the company with milestone payments based on global sales performance.
  • Ampreloxetine: Investigational medicine for multiple system atrophy; currently being wound down following results from recent clinical studies.
  • Pipeline Programs: Research-stage treatments for gut and lung conditions; designed to target specific organs to reduce body-wide side effects.

Strategic Shifts and Partnerships

  • Sold the remaining royalty interest in TRELEGY global sales to GSK in June 2025 for $225 million.
  • Received a $25 million milestone payment from Viatris in January 2026 after YUPELRI reached annual sales targets.
  • Secured regulatory approval for YUPELRI in China through a partnership with Viatris in June 2025.
  • Partnered with Royalty Pharma in 2022 to secure funding for the development of blood pressure treatments.

What Sets the Company Apart

The firm focuses on organ-selective therapies designed to treat specific body parts while limiting drug exposure to the rest of the body. It uses a partnership model to share commercial costs while maintaining its own specialized sales force for hospital settings.

A Look at the Numbers

  • Revenue reached $45.9 million in Q4 2025, up 144.7% from Q4 2024.
  • Net income turned positive at $61 million in Q4 2025, up from a $15.5 million loss in Q4 2024.
  • Operating income improved to $10.4 million in Q4 2025, compared to a $9.2 million loss in Q4 2024.
  • Total YUPELRI net sales grew 12% to $266.6 million in 2025 compared to 2024.
  • Free cash flow worsened to negative $6.1 million in Q4 2025, down from negative $1.1 million in Q4 2024.

The Path Ahead

Theravance Biopharma is shifting from broad drug discovery toward a leaner structure focused on its primary respiratory product. This evolution includes a strategic review and significant cost reductions to align resources with its commercial goals.

AI Generated • May 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

90

CEO

Rick E. Winningham, MBA

Website

www.theravance.com

Headquarters

South San Francisco, CA 94080, US

TBPH Financials

Key Financial Metrics (TTM)

Gross Margin

89.40%

Operating Margin

4.46%

Net Income Margin

51.58%

Return on Equity

19.40%

Return on Capital

-3.56%

Return on Assets

11.45%

Earnings Yield

5.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$878.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.92M

Volume

47.95K

Avg. Volume

642.09K

Financials (TTM)

Gross Profit

$93.25M

Operating Income

$4.66M

EBITDA

$68.46M

Operating Cash Flow

$51.83M

Capital Expenditure

-$8.00K

Free Cash Flow

$51.82M

Cash & ST Invst.

$387.66M

Total Debt

$38.57M

Theravance Biopharma Performance Analysis

Theravance Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 51,346,000-7.2%
20232023-12-31USD 57,424,00011.8%
20242024-12-31USD 64,381,00012.1%
20252025-12-31USD 107,464,00066.9%
Theravance Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-23.7%
Q42025-12-31129.6%
Q12026-03-31-61.4%
Q22026-06-3017.1%
Theravance Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.6527.3%
20232023-12-31USD -1.00-72.7%
20242024-12-31USD -1.1615.7%
20252025-12-31USD 2.06N/A
Theravance Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-93.5%
Q42025-12-311542.9%
Q12026-03-31-108.4%
Q22026-06-30-14.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$20.73M

-20.9%

Gross Profit

$19.29M

+22.8%

Gross Margin

93.04%

N/A

Market Cap

$878.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.76M

N/A

Employees

90

N/A

Net Income

-$5.90M

-110.8%

EBITDA

$839.00K

-98.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$387.66M

+14.4%

Total Debt

$38.57M

-17.0%

Accounts Receivable

$20.38M

-7.0%

Inventory

$0.00

N/A

Long Term Debt

$27.77M

-21.9%

Short Term Debt

$10.80M

-0.9%

Return on Assets

11.45%

N/A

Return on Invested Capital

1.06%

N/A

Free Cash Flow

-$8.88M

-104.3%

Operating Cash Flow

-$8.88M

-104.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GERNGeron Corporation
$1.52-0.65%
BTXBlackRock Innovation and Growth Term Trust
$8.99-2.86%
VALNValneva SE
$6.88-2.50%
GLUEMonte Rosa Therapeutics, Inc.
$15.11-1.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.50-0.01%
NOKNokia
$10.37-0.04%
INTCIntel
$95.90-0.07%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$125.75-0.17%

Questions About TBPH

What is the current price of Theravance Biopharma?

Theravance Biopharma is trading at $16.95 per share.

What is the 52-week range for Theravance Biopharma?

Over the past 52 weeks, Theravance Biopharma has traded between $13.08 and $21.03.

How much debt does Theravance Biopharma have?

As of the most recent reporting period, Theravance Biopharma reported total debt of $71.36M.

How much cash does Theravance Biopharma have on hand?

Theravance Biopharma reported $219.77M in cash and cash equivalents in its most recent financial results.

What is Theravance Biopharma’s dividend yield?

Theravance Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services